The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index; 29 of the 44 sources its claims cite were checked for support.
Overexpressing low‐density lipoprotein receptor reduces tau‐associated neurodegeneration in relation to apoE‐linked mechanisms
Open accessAbstract
APOE is the strongest genetic risk factor for late-onset Alzheimer's disease. ApoE exacerbates tau-associated neurodegeneration by driving microglial activation. However, how apoE regulates microglial activation and whether targeting apoE is therapeutically beneficial in tauopathy is unclear. Here, we show that overexpressing an apoE metabolic receptor, LDLR (low-density lipoprotein receptor), in P301S tauopathy mice markedly reduces brain apoE and ameliorates tau pathology and neurodegeneration. LDLR overexpression (OX) in microglia cell-autonomously downregulates microglial Apoe expression and is associated with suppressed microglial activation as in apoE-deficient microglia. ApoE deficiency and LDLR OX strongly drive microglial immunometabolism toward enhanced catabolism over anabolism, whereas LDLR-overexpressing microglia also uniquely upregulate specific ion channels and neurotransmitter receptors upon activation. ApoE-deficient and LDLR-overexpressing mice harbor enlarged pools of oligodendrocyte progenitor cells (OPCs) and show greater preservation of myelin integrity under neurodegenerative conditions. They also show less reactive astrocyte activation in the setting of tauopathy.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
Overexpressing LDLR in P301S tauopathy mice markedly lowers brain apoE and reduces tau pathology, neurodegeneration, synaptic loss, and microglial activation. The protective effects are linked to apoE-dependent microglial metabolic reprogramming, with additional preservation of myelin and OPC pools.
Key findings
- LDLR overexpression (OX) in P301S mice at 9 months reduced brain atrophy, synaptic loss, and postsynaptic density loss, and shifted p-tau staining toward an early-disease pattern; CSF and soluble brain apoE were reduced by ~90%, and p-tau was significantly reduced in RAB and RIPA fractions, while total human tau was unchanged.
- Microglial LDLR OX cell-autonomously downregulated microglial *Apoe* expression and intracellular apoE, and was associated with suppressed microglial activation; in 20-month mice, LDLR microglia showed reduced “DAM” and proinflammatory gene expression, and P301S/LDLR mice had less CD68+ microglial activation than P301S mice.
- snRNAseq of 31,785 nuclei identified 10 cell clusters; microglial subclustering found a P301S-enriched DAM cluster, a P301S/LDLR-unique cluster, and an apoE-deficiency-associated cluster. ApoE-deficient and LDLR microglia shifted toward catabolism with upregulated lysosomal genes and LGMN, downregulated anabolic/mTOR pathways, and LDLR microglia uniquely upregulated ion channels and neurotransmitter receptors.
- ApoE-deficient and LDLR-overexpressing mice had enlarged OPC pools and greater myelin preservation: OPC cluster representation was ~20% in EKO/P301S/EKO, 10–13% in LDLR/P301S/LDLR, and 3–5% in WT/P301S; P301S/LDLR and P301S/EKO mice also showed less demyelination and lower axonal G-ratio than P301S mice, with less reactive astrocyte activation.
Methods
- LDLR Tg mice were crossed to P301S and apoE KO mice; experiments used male mice except where stated, at ages including 3, 9, 20, and 24 months, with primary microglia, acutely isolated microglia, FACS, qPCR, western blot, ELISA, immunohistochemistry, electron microscopy, and lysosomal enzyme activity assays.
- Single-nuclei RNAseq used 10x Genomics on pooled hippocampi from 7–8 mice per genotype, yielding 31,785 nuclei; Seurat was used for clustering, MAST for differential expression, and Metascape for pathway analysis.
- Statistics used mean ± SEM, normality testing, t-tests or one-way ANOVA with Tukey post hoc, or Mann-Whitney/Kruskal-Wallis with Dunn’s post hoc, with significance thresholds *p*<0.05 to *p*<0.0001.
Limitations
- The paper states that further study is required to carefully address whether LDLR affects pathological tau spreading, and that functional characterization of reactive astrocytes in neurodegeneration needs future studies.
- Evident from the text: snRNAseq pooled 7–8 mice per genotype into a single sample per genotype, limiting animal-level statistical inference for transcriptomic comparisons.
- Evident from the text: male mice were used for all experiments except a few cases where sex was specifically stated, limiting generalization across sexes; the paper also notes that absolute tau and p-tau ELISA values cannot be directly compared because of different standards and antibody-binding capacities.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
29 of 44 cited sources checked · 22 supported · 1 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“ApoE had a strong immunomodulatory function and promoted neurodegeneration and tau pathogenesis predominantly by driving microglial activation (Shi et al., 2019).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Supportedcites Shi et al., 2019 source
The Discussion states that microglial depletion eliminated apoE’s effect on neurodegeneration and abolished its effects on phosphorylated-tau progression in the tauopathy mouse model. It concludes that apoE’s effects on both are primarily mediated through microglial function; the Introduction also describes apoE as a potent immune modulator. (LLM, conf=0.93)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ApoE ablation in P301S tau transgenic (Tg) mice markedly reduced brain atrophy and tau pathology compared to the presence of apoE, whereas apoE4 significantly exacerbated neurodegeneration compared to apoE2 and apoE3 (Shi et al., 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Partly supportedcites Shi et al., 2017 sourceExperimental — accuracy not yet measured
The paper reports that ApoE knockout largely attenuated brain atrophy in P301S mice expressing human ApoE. It also reports differences in tau pathology across ApoE genotypes, but not a marked overall reduction in tau pathology with knockout: at 9 months, overall p-tau staining differences had decreased, although staining patterns differed. The reported greater neurodegeneration with ApoE4 than with ApoE2 or ApoE3 is supported (main text, passages indexed under Abstract; page unavailable). (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“microglia-derived apoE was shown to cell-autonomously promote microglial activation towards the neurodegenerative “MGnD/DAM” phenotype (Krasemann et al., 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Microglial overexpression of the LDLR transgene reduces microglial Apoe expression and intracellular apoE level and is associated with less microglial activation
What the sources say
- Supportedcites Krasemann et al., 2017 source
The Results section reports that deleting Apoe specifically in microglia repressed a disease-associated gene and restored homeostatic genes in phagocytic microglia. The Discussion explicitly describes APOE regulation of the MGnD phenotype as cell-autonomous. Page numbers were not supplied in our copy. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“ApoE ablation in P301S tau transgenic (Tg) mice markedly reduced brain atrophy and tau pathology compared to the presence of apoE, whereas apoE4 significantly exacerbated neurodegeneration compared to apoE2 and apoE3 (Shi et al., 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Supportedcites Shi et al., 2017 source
The passage labeled Abstract reports significantly more brain atrophy in nine-month-old P301S/E4 mice than in P301S/E2 and P301S/E3 mice. It identifies this as more severe tau-mediated neurodegeneration with ApoE4. (LLM, conf=0.94)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Low-density lipoprotein receptor (LDLR) is one of the two primary metabolic receptors (the other is low-density lipoprotein receptor-related protein 1, LRP1) mediating the clearance of apoE lipoproteins (Holtzman et al., 2012; Ishibashi et al., 1994).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Supportedcites Holtzman et al., 2012 source
The section “Evidence that LRP1 and LDLR Are Key Metabolic Receptors for ApoE/Lipoprotein in the Brain” explicitly identifies LDLR and LRP1 as the two primary metabolic receptors for apoE/lipoprotein. It also describes changes in brain apoE levels when LDLR expression is altered, consistent with a role in its clearance. (LLM, conf=0.95)
- Partly supportedcites Ishibashi et al., 1994 sourceExperimental — accuracy not yet measured
The Discussion supports LDLR as one of two receptors involved in apoE-mediated lipoprotein clearance. It cautions, however, that the identity of the second receptor is not known for certain, so the citing sentence’s definite identification of it as LRP1 goes beyond the paper’s conclusion. Page numbers are not given in the supplied passages. (LLM, conf=0.84)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“We and others subsequently identified microglia as the principal driving force of neurodegeneration and tau pathogenesis in tauopathy mouse models (Mancuso et al., 2019; Shi et al., 2019).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Partly supportedcites Mancuso et al., 2019 sourceExperimental — accuracy not yet measured
The Discussion reports that inhibiting microglial proliferation in P301S mice prevented neurodegeneration and potentially slowed tau aggregation. It describes activated microglia as deleterious, but does not establish them as the principal driving force of either process across tauopathy mouse models; it explicitly notes uncertainty about whether their effect on tau pathology is predominant. The indexed passages provide section labels but no page numbers. (LLM, conf=0.86)
- Supportedcites Shi et al., 2019 source
The Discussion states that microglial activation drives neurodegeneration in the studied tauopathy mouse model and that microglia drive progression of phosphorylated-tau pathology. This supports the claim attributed to Shi et al.; the sentence’s plural “models” refers to the studies cited together, while this paper provides evidence from one model. (LLM, conf=0.93)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDLR mice also showed a moderate increase in enzyme activities compared to WT mice (Figure 5K)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > ApoE deficiency boosts microglial lysosomal enzyme activities under physiological conditions, and reduces microglial mTOR activation and lipid/cholesterol accumulation upon microglial activation
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Similar differences were also observed in tau Tg mice (Figure 7B, C).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > ApoE-deficient and LDLR-overexpressing mice harbor enlarged pools of oligodendrocyte progenitor cells in the brain and show greater preservation of myelin integrity under neurodegenerative conditions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Corresponding to LDLR OX, apoE levels in the CSF of LDLR and P301S/LDLR mice were markedly reduced by ~90% compared to WT and P301S mice respectively (Figure 2A).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > LDLR OX in P301S mice leads to a marked reduction of apoE and p-tau levels that strongly correlate with each other
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the absence of the tau transgene, apoE- and LDLR-associated gene expression changes (WT vs. EKO or WT vs. LDLR) were primarily enriched in neurons, particularly in excitatory neurons.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Single-nuclei RNAseq identifies changes in distinct brain cell populations and in cell-type-specific DEGs under neurodegenerative, apoE-deficient and LDLR-OX conditions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 31
- It may state two separate claims as one. 37
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“In a normal brain, apoE is produced predominantly by astrocytes, and to a much less extent, by microglia (Boyles et al., 1985; Uchihara et al., 1995).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Apoe expression is upregulated uniquely in microglia over other brain cell types in tau-associated neurodegeneration
What the sources say
- Disputedcites Boyles et al., 1985 sourceExperimental — accuracy not yet measured
The Abstract reports apoE in astrocytes of rat brain but says it was not present in microglia. The Discussion likewise says most cells identified as microglia were negative for apoE immunoreactivity. The source therefore supports astrocytic production, but not the claim that normal-brain microglia produce apoE to a lesser extent. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites Uchihara et al., 1995 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Disputed
Every source the paper cites for this claim was checked and supports it.
In the paper
“Astrocytes are another major immune-competent cell population in the brain, and have long been proposed to play a role in neurodegeneration (Ben Haim et al., 2015; Liddelow et al., 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Astrocyte sub-clustering identifies features of homeostatic and reactive astrocytes
What the sources say
- Supportedcites Ben Haim et al., 2015 source
The Introduction states that reactive astrocytes and microglia mediate innate immune responses in the brain and that astrocytes become reactive during progressive neurodegenerative diseases. The disease-models section discusses astrocyte cytokine production in Alzheimer’s disease and inflammatory changes in ALS, supporting their proposed role in neurodegeneration. (LLM, conf=0.91)
- Supportedcites Liddelow et al., 2017 source
The Introduction describes astrocytes as abundant CNS cells that phagocytose synapses and respond to brain injury and disease. The section on human disease reports A1-like astrocytes in major neurodegenerative diseases, while the Concluding Remarks discuss their complement production and possible role in CNS immune responses. Together, these support the broad description of astrocytes as immune-competent cells implicated in neurodegeneration. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Microglia express major classes of neurotransmitter receptors and ion channels that critically regulate microglial physiology, which inherently controls microglial function and activation (Domercq et al., 2013; Izquierdo et al., 2019).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > LDLR-associated microglia upregulate genes encoding specific subsets of ion channels and neurotransmitter receptors and downregulate microglial activation pathways
What the sources say
- Not matchedcites Domercq et al., 2013
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Supportedcites Izquierdo et al., 2019 source
The Abstract states that essential microglial functions depend on ion channels, and the section on complex functions says ion channels and cell-surface receptors regulate microglial surveillance. The section on ramification and surveillance also describes adenosine, purinergic and adrenergic receptors in relation to microglial activation and process behavior. Together, these passages support the broad paraphrase. (LLM, conf=0.89)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Not matched
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“ApoE strongly regulates brain amyloid-β (Aβ) deposition in a dose- and isoform-dependent manner (E4>E3>E2) (Bales et al., 1997; Holtzman et al., 2000; Schmechel et al., 1993).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Not checked — no full text of the sourcecites Bales et al., 1997 source
- Partly supportedcites Holtzman et al., 2000 sourceExperimental — accuracy not yet measured
The Results section reports greater Aβ deposition in apoE4- than apoE3-expressing mice, supporting the E4>E3 comparison. The paper does not test apoE2 or establish the claimed dose-dependent relationship; its Discussion proposes a concentration threshold rather than demonstrating a dose-response. Page numbers were not available in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Schmechel et al., 1993 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Microglial depletion in P301S mice fully blocked neurodegeneration and stopped tau pathology progression.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Supportedcites Shi et al., 2019 source
The Results section reports that microglial depletion in TE4 mice, a P301S tauopathy model, virtually fully blocked neurodegeneration. The Discussion states that depletion fully blocked brain atrophy and halted progression of phosphorylated tau pathology. (LLM, conf=0.91)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In an LDLR transgenic (Tg) mouse line, a PrP-driven Ldlr transgene was shown to be overexpressed in neurons and astrocytes by 10-fold, resulting in ~90% reduction of brain soluble apoE (Kim et al., 2009)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Supportedcites Kim et al., 2009 source
The Results (Generation and Characterization of LDLR Transgenic Mice; page not provided) describe a mouse-prion-promoter LDLR transgene, greater than tenfold overexpression in line B, and elevated LDLR in both neurons and astrocytes. The Results (LDLR Overexpression Decreases ApoE Levels; page not provided) report approximately 90% lower soluble apoE in cortical and hippocampal tissue from line B mice. (LLM, conf=0.91)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“LDLR Tg mice were generated in house previously on a B6/CBA background expressing murine LDLR under the PrP promoter (Kim et al., 2009).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > EXPERIMENTAL MODEL AND SUBJECT DETAILS
What the sources say
- Supportedcites Kim et al., 2009 source
The Experimental Procedures section, “Generation of LDLR Transgenic Mice” (page not provided), states that murine LDLR cDNA was inserted into a mouse prion promoter vector and that Washington University’s Mouse Genetics Core produced the transgenic mice on a B6/CBA background. The Results section confirms that the founders were maintained on that background. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“and is largely mediated by voltage-gated K+ channels, particularly Kv1.3, which critically regulates proinflammatory cytokine generation (Di Lucente et al., 2018).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Di Lucente et al., 2018 source
In the Results (page unavailable), LPS-stimulated mouse microglia showed outward voltage-gated K+ currents carried predominantly by Kv1.3, with some residual current in a small subset of cells. The Results also report that Kv1.3 knockout substantially reduced LPS-induced IL-1β and TNF-α levels and suppressed pro-inflammatory gene expression in microglia. The evidence supports the claim in the paper’s microglial, LPS-stimulated setting. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“ApoE’s effect appears to occur mainly in a cell-autonomous manner by regulating cellular cholesterol content, which critically regulates the level of membrane-associated signaling complexes that are essential for triggering cell proliferation (Murphy et al., 2011).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Murphy et al., 2011 source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The defective anabolic and energetic metabolism in TREM2-deficient microglia was shown to underlie their ineffective activation.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Ulland et al., 2017 source
The Results section reports impaired anabolic and energetic metabolism in TREM2-deficient microglia. The Discussion states that defective mTOR signaling severely impairs their capacity to respond to Aβ accumulation, supporting the claimed link between metabolic dysfunction and ineffective activation; page numbers were not available in our copy. (LLM, conf=0.91)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“TREM2-deficient microglia were reported to have increased autophagy and catabolism, impaired mTOR activation and anabolism, and reduced ATP production (Ulland et al., 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Partly supportedcites Ulland et al., 2017 sourceExperimental — accuracy not yet measured
The Results section on microglia reports increased autophagy, impaired mTOR signaling, and disrupted anabolic and energetic metabolism in TREM2-deficient microglia. The direct findings of increased catabolic products and depleted ATP are reported in bone marrow-derived macrophages, not microglia; ATP levels also do not directly establish reduced ATP production. The copy provides no page numbers for these passages. (LLM, conf=0.88)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Microglia express a broad spectrum of neurotransmitter receptors and ion channels that critically regulate microglial functions such as surveillance (Madry et al., 2018), cytokine release (Nguyen et al., 2017), chemotaxis, and phagocytosis (Haynes et al., 2006; Koizumi et al., 2007; Ohsawa et al., 2007).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Madry et al., 2018 source
Madry et al. is cited for surveillance, not for the separately cited functions in the sentence. In Results, the paper reports that blocking THIK-1 inhibited microglial surveillance and that THIK-1 knockout reduced surveillance in brain slices and in vivo. (LLM, conf=0.94)
- Supportedcites Nguyen et al., 2017 source
The Nguyen et al. citation is attached specifically to cytokine release, not to surveillance, chemotaxis, or phagocytosis. The Abstract reports that blocking Kv1.3 or KCa3.1 inhibited pro-inflammatory cytokine production in microglia, and the Discussion identifies IL-1β and TNF-α among the affected cytokines. (LLM, conf=0.93)
- Partly supportedcites Haynes et al., 2006 sourceExperimental — accuracy not yet measured
The chemotaxis experiments (p. 43) show that P2Y12-deficient microglia lack directed movement toward ADP or ATP, supporting the receptor-regulated chemotaxis portion of the citation. The Introduction (Chapter 1) says activated microglia can phagocytose debris, but the cited paper does not show that receptors or ion channels regulate phagocytosis. The paper discusses several purinergic receptors rather than establishing the full breadth of neurotransmitter receptors and ion channels in the citing sentence. (LLM, conf=0.87)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The ability of apoE to inhibit cell proliferation has also been reported in other cell types, such as hippocampal neural stem/progenitor cells (NSC/NPC) (Yang et al., 2011) and hematopoietic cells (Murphy et al., 2011).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Yang et al., 2011 source
The rescue experiment reports that re-expressing ApoE reduced BrdU incorporation in neural progenitor cells. The Discussion also states that ApoE inhibits neural stem/progenitor-cell proliferation in the dentate gyrus. Yang et al. is cited for the hippocampal-cell part of the sentence, not the hematopoietic-cell part; page numbers are not provided in our copy. (LLM, conf=0.94)
- Supportedcites Murphy et al., 2011 source
The Murphy et al. citation is attached to hematopoietic cells, not hippocampal neural stem/progenitor cells. The Discussion reports that ApoE suppresses proliferation of hematopoietic stem and progenitor cells (HSPCs); the supplied passage does not specify a page. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The other primary apoE metabolic receptor, LRP1, has been shown to mediate tau uptake in vitro and drastically increase the propagation of the P301L human tau protein expressed by an AAV virus in vivo (Rauch et al., 2020)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Rauch et al., 2020 source
The Results report that LRP1 knockdown reduced tau uptake in cultured cells and greatly diminished tau spread in mice compared with controls. The Methods (Animals; page not specified) identify the in vivo construct as AAV-encoded human tau P301L. (LLM, conf=0.92)
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“APOE and TREM2 act in the same axis in regulating many aspects of microglial functions (Shi and Holtzman, 2018).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Shi and Holtzman, 2018 source
The review describes an ApoE–TREM2 axis in microglial phagocytosis (Immune functions of ApoE in neurodegeneration) and shared pathways regulating the microglial neurodegenerative phenotype (same section). It also links both proteins to microglial responses to amyloid-β plaques (ApoE and amyloid-β pathology), supporting the claim across multiple functions. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent study shows that selective removal of astrocyte-derived apoE4 (but not apoE3) reduces tau-associated neurodegeneration (Wang et al., 2021).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Wang et al., 2021 source
The Discussion (page unavailable) states that genetic deletion of astrocytic APOE4, but not APOE3, was significantly neuroprotective in P301S Tau mice. This directly supports the cited comparison in a mouse model of tauopathy. (LLM, conf=0.95)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Interestingly, TREM2 deficiency also protects against tau-associated neurodegeneration in P301S mice (Leyns et al., 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Supportedcites Leyns et al., 2017 source
The Results section identifies PS19 mice as expressing P301S-mutant human tau and reports less brain atrophy and synaptic degeneration in TREM2-deficient PS19 mice than in controls. The authors conclude that loss of TREM2 function is neuroprotective in this tauopathy model; the study examined male mice only. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas minimal levels of these gene expression changes and no differences in their expression level were observed in microglia isolated from 3-month mice (Figure 3K).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Microglial overexpression of the LDLR transgene reduces microglial Apoe expression and intracellular apoE level and is associated with less microglial activation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“cluster 2 was specifically enriched in P301S mice (Figure 5A, B), and featured hallmark “DAM/MGnD” genes such as Apoe, Spp1, Cd74, Lilrb4a, Itgax, Axl, Trem2 and B2m (Figure 5C, E)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Microglia sub-clustering reveals distinct microglial subpopulations associated with neurodegeneration, apoE deficiency, or LDLR-OX
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDLR OX in P301S mice attenuated tau pathology, shifting p-tau staining towards an early-disease pattern (type1) (Figure 1H).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > LDLR OX in P301S mice attenuates neurodegeneration, synaptic loss and tau pathology
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared to cluster 2 “DAM” microglia, a prominent feature of cluster 4 microglia was upregulation of catabolic genes, and downregulation of anabolic genes as well as microglial activation pathways (Figure 5F).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > ApoE deficiency-associated microglia downregulate anabolic pathways and show robust upregulation of catabolic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neurodegeneration in P301S mice featured loss of specific subtypes of excitatory hippocampal neurons, including dentate gyrus (DG), CA1 and CA3 neurons, particularly DG neurons, but had little impact on subiculum neurons (Figure 4C, D).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Single-nuclei RNAseq identifies changes in distinct brain cell populations and in cell-type-specific DEGs under neurodegenerative, apoE-deficient and LDLR-OX conditions
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in P301S mice, apoE immunostaining revealed intracellular apoE accumulation as large bright puncta in activated microglia; whereas in WT mice, apoE signal was primarily present in astrocytes (Figure S4B).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Apoe expression is upregulated uniquely in microglia over other brain cell types in tau-associated neurodegeneration
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We obtained sequencing data from a total of 31785 nuclei, and identified 10 distinct cell clusters across all samples based on the expression of known cell-type-specific markers”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Single-nuclei RNAseq identifies changes in distinct brain cell populations and in cell-type-specific DEGs under neurodegenerative, apoE-deficient and LDLR-OX conditions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We performed sub-clustering of astrocytes (pooled from all samples, a total of 1863 nuclei), and identified homeostatic astrocyte populations and a reactive astrocyte subset, as well as a subpopulation of astrocytes enriched in apoE-deficient mice (EKO and P301S/EKO) (Figure 6A, B).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Astrocyte sub-clustering identifies features of homeostatic and reactive astrocytes
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Notably, cluster 3 was uniquely enriched in P301S/LDLR mice (Figure 5A, B), but not in LDLR mice”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Microglia sub-clustering reveals distinct microglial subpopulations associated with neurodegeneration, apoE deficiency, or LDLR-OX
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Compared to P301S mice, Apoe expression in P301S/LDLR mice was notably lower in microglia, but was only mildly reduced in astrocytes (Figure S4A)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Apoe expression is upregulated uniquely in microglia over other brain cell types in tau-associated neurodegeneration
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We verified by immunofluorescent staining (GFAP, Vimentin) that reactive astrocytes were highly activated in 9-month P301S mice, but were only mildly increased in P301S/LDLR and P301S/EKO mice (Figure 6F).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Astrocyte sub-clustering identifies features of homeostatic and reactive astrocytes
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Biochemically, no differences in tau or ptau levels were detected despite a similar level of apoE reduction in P301S/LDLR mice (Figure S2C).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > LDLR OX does not affect tau pathology and brain volume at an early age prior to microglial activation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found microglial Apoe expression was significantly elevated in 20-month WT mice, but not in 20-month LDLR Tg mice compared to their 3-month counterparts (Figure 3J).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Microglial overexpression of the LDLR transgene reduces microglial Apoe expression and intracellular apoE level and is associated with less microglial activation
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We confirmed higher expression of top upregulated genes such as Gabra6 and Grm4 in acutely isolated microglia from 20-month LDLR Tg mice compared to WT mice, whereas no differences were observed in 3-month mice (Figure S5C, D).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > LDLR-associated microglia upregulate genes encoding specific subsets of ion channels and neurotransmitter receptors and downregulate microglial activation pathways
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Notably, microglia were markedly increased in P301S mice, and were only mildly increased in P301S/LDLR and P301S/EKO mice”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Single-nuclei RNAseq identifies changes in distinct brain cell populations and in cell-type-specific DEGs under neurodegenerative, apoE-deficient and LDLR-OX conditions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Reduction of microglial Apoe expression (Figure 3G) and intracellular apoE protein levels was also observed in acutely-isolated LDLR Tg microglia (Figure 3H, I).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Microglial overexpression of the LDLR transgene reduces microglial Apoe expression and intracellular apoE level and is associated with less microglial activation
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In contrast, upregulated pathways featured “regulation of synaptic plasticity”, “regulation of ion transport”, and “regulation of membrane potential”.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > LDLR-associated microglia upregulate genes encoding specific subsets of ion channels and neurotransmitter receptors and downregulate microglial activation pathways
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Through electron microscopy, we also identified notable signs of myelin damage in the corpus callosum of 9-month P301S mice, which showed a significantly higher percentage of demyelinated axons as well as increased axonal G-ratio compared to 9-month P301S/LDLR and P301S/EKO mice, or 3-month P301S mice (Figure 7F, G).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > ApoE-deficient and LDLR-overexpressing mice harbor enlarged pools of oligodendrocyte progenitor cells in the brain and show greater preservation of myelin integrity under neurodegenerative conditions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“these effects were either not present or only weakly showed up in oligodendrocytes.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A portion of microglia from all 6 groups of mice show expression of certain oligodendrocyte genes”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedn = 6Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas apoE deficiency-associated microglia showed enhanced catabolism and suppressed anabolism.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“LDLR Tg microglia showed a similar metabolic pattern and reduced activation as apoE-deficient microglia, likely in part due to cell-autonomous reduction in Apoe expression.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Axonal demyelination and altered G-ratio also occurred in the corpus callosum of 24-month old WT mice relative to 9-month WT mice, and this damage was significantly attenuated in 24-month LDLR Tg and EKO mice (Figure S6A-C).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > ApoE-deficient and LDLR-overexpressing mice harbor enlarged pools of oligodendrocyte progenitor cells in the brain and show greater preservation of myelin integrity under neurodegenerative conditions
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we find LDLR OX leads to a strong reduction in extracellular apoE levels and microglial Apoe downregulation that are directly linked with suppressed microglial activation.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Activated immune cells increase anabolism and rewire their metabolism towards enhanced glycolysis (Bories and Leitinger, 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > ApoE deficiency-associated microglia downregulate anabolic pathways and show robust upregulation of catabolic genes
What the sources say
- Not checked — no full text of the sourcecites Bories and Leitinger, 2017 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“APOE4 strongly increases the risk of developing late-onset Alzheimer’s disease (AD), whereas APOE2 reduces AD risk relative to APOE3 (Bu, 2009).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Introduction
What the sources say
- Not matchedcites Bu, 2009
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
In the paper
“ApoE expression in neurons is minimal under physiological conditions, but can be upregulated upon neuronal injury in certain conditions (Xu et al., 2006).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Results > Apoe expression is upregulated uniquely in microglia over other brain cell types in tau-associated neurodegeneration
What the sources say
- Not matchedcites Xu et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 31,785 individual nuclei across all genotypes remained, with a median of 1,620 UMIs and 871 genes per nucleus for downstream analysis.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedn = 31,785Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“In addition, the high expression of GABA receptor (Gabra6, second most enriched DEG in cluster3 microglia) may also play a role in inhibiting microglial cytokine release (Kuhn et al., 2004) and attenuating microglial activation.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Not checked — no full text of the sourcecites Kuhn et al., 2004 source
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Proinflammatory “M1” microglia show a profound metabolic change characterized by increased glucose uptake and a switch from oxidative phosphorylation (OXPHOS) to glycolysis even in normoxic conditions (Warburg effect) (Bories and Leitinger, 2017).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Not checked — no full text of the sourcecites Bories and Leitinger, 2017 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Microglia derived from individual P2 pups (mixed sex) were cultured separately as independent samples.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Oligodendrocyte genes and pathways showing up in microglial analysis results were excluded.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedn = 6Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“LDLR OX also increases the OPC population, which is likely due to apoE reduction, or may also be contributed by a direct effect of LDLR on cellular lipid/cholesterol homeostasis.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ApoE reduction doesn’t affect early tau pathology prior to microglial activation, suggesting that its protective effect on tau pathology is likely carried out at a later stage by regulating microglial activation under neurodegenerative conditions.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For quality control, nuclei with mitochondrial content >5% were removed.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“filter reads with a quality score below 30.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Modulating LRP1 has also been reported to affect brain apoE levels (Liu et al., 2007; Zerbinatti et al., 2006)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted P-value was calculated using Bonferroni correction.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Development of outward K+ current in microglia is associated with an advanced microglial activation status (Boucsein et al., 2000; Wendt et al., 2017)”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For all experiments, data normality was analyzed using D’Agostino-Pearson omnibus normality test.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The Kv3 channels have a 10-50 mV higher activation threshold than any other known mammalian voltage-gated K+ channels (Coetzee et al., 1999).”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > Discussion
What the sources say
- Not checked — no full text of the sourcecites Coetzee et al., 1999 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“ptau ELISA detects ptau species that have phosphorylation at both Thr181 and Ser202/Thr205 epitopes, which represent hyperphosphorylated ptau.”
§ Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms > STAR★Methods > METHOD DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Male P301S mice start developing overt tau pathology from ~5-6 months of age and show severe brain atrophy at 9 months of age.
“Male P301S mice start developing overt tau pathology from ~5-6 months of age and show severe brain atrophy at 9 months of age.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“As these molecules play critical roles in Aβ clearance and tau aggregation,41,42 the ε7 isoform may influence AD pathology through these pathways.”
From Association of rare APOE missense variants with Alzheimer's disease in the Japanese population (2025) · cites this paper as [42]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Therefore, apoE4 accelerates AD pathogenesis by inducing dysregulation of microglia and astrocytes and provoking neuroinflammation”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Shi et al 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“overexpression of LDLR is an effective approach to significantly induce apoE reduction and consequent alleviation of pathological changes in AD mouse models”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Shi et al 2021
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“It is notable that overexpression of Ldlr also reduced tau pathology and neurodegeneration in a tauopathy mouse model,”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“previous studies have demonstrated that deletion of Apoe and overexpression of Ldlr can reduce tau‐associated neurodegeneration.”
From Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors (2025) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of LDLR reduced ApoE levels and reduced tau-mediated neurodegeneration (63).”
From Regulation of astrocyte lipid metabolism and ApoE secretion by the microglial oxysterol, 25-hydroxycholesterol (2023) · cites this paper as [63]
The cited source says what the claim attributes to it.
In the citing paper
“important roles were shown for LDLR in modulating AD pathologies57–59, in part via uptake and clearance of Aβ by astrocytes60.”
From Decreased lipidated ApoE‐receptor interactions confer protection against pathogenicity of ApoE and its lipid cargoes in lysosomes (2025) · cites this paper as [59]
The cited source says what the claim attributes to it.
In the citing paper
“Shi et al. [86] report that overexpression of LDLR in PS19 mice suppresses microglial activation, enlarges pools of oligodendrocyte progenitor cells, and enhances preservation of myelin integrity.”
From APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology (2025) · cites this paper as [86]
The cited source says what the claim attributes to it.
In the citing paper
“Apoe knockout mice and LDL receptor (Ldlr)-overexpressing mice — which display low levels of APOE owing to internalization and clearance of APOE lipoproteins — have larger pools of oligodendrocyte progenitor cells and increased myelin coverage of axons, supporting the idea that APOE regulates oligodendrocyte number and function106.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [106]
The cited source says what the claim attributes to it.
In the citing paper
“overexpression of LDLR in PS19 tauopathy mice also results in a significant reduction of brain apoE levels and inhibition of tau phosphorylation, which strongly correlate with one another, and consequent amelioration of tau pathology and neurodegeneration”
From ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease (2022) · cites this paper as Shi et al 2021
The cited source says what the claim attributes to it.
In the citing paper
“Overexpression of the ApoE receptor LDLR in the brain decreases tau mediated neurodegeneration [90].”
From ApoE lipoproteins in the central nervous system under homeostasis and role in Alzheimer’s disease and related disorders (2026) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
The stated Naglu substrate has the wrong linkage
MajorThe paper identifies Naglu as an α-glucosaminidase but lists a β-linked substrate for its activity assay. Cleavage of that substrate would not specifically measure the stated Naglu activity, undermining the reported increase in activity for that enzyme.
“N-Acetyl-Alpha-Glucosaminidase (Naglu)”
“4-Methylumbelliferyl N-acetyl-β-D-glucosaminide (Naglu Substrate)”
Citations
Cites
Integrating single-cell transcriptomic data across different conditions, technologies, and species
Butler, A., Hoffman, P., Smibert, P., Papalexi, E., & Satija, R. (2018) · Nature Biotechnology · doi:10.1038/nbt.4096 · Cited by 13,174
Neurotoxic reactive astrocytes are induced by activated microglia
Liddelow, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., Bennett, M. L., Münch, A. E., Chung, W.-S., Peterson, T. C., et al. (2017) · Nature · doi:10.1038/nature21029 · Cited by 7,971
Cell types in the mouse cortex and hippocampus revealed by single-cell RNA-seq
Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S., Lönnerberg, P., La Manno, G., Juréus, A., Marques, S., Munguba, H., He, L., Betsholtz, C., et al. (2015) · Science · doi:10.1126/science.aaa1934 · Cited by 3,124
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
Self-citationSingle-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568
The P2Y12 receptor regulates microglial activation by extracellular nucleotides
Haynes, S. E., Hollopeter, G., Yang, G., Kurpius, D., Dailey, M. E., Gan, W.-B., & Julius, D. (2006) · Nature Neuroscience · doi:10.1038/nn1805 · Cited by 1,542
Schmechel, D. E., Saunders, A. M., Strittmatter, W. J., Crain, B. J., Hulette, C. M., Joo, S. H., Pericak-Vance, M. A., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.20.9649 · Cited by 1,525
TREM2 Maintains Microglial Metabolic Fitness in Alzheimer’s Disease
Ulland, T. K., Song, W. M., Huang, S. C.-C., Ulrich, J. D., Sergushichev, A., Beatty, W. L., Loboda, A. A., Zhou, Y., Cairns, N. J., Kambal, A., et al. (2017) · Cell · doi:10.1016/j.cell.2017.07.023 · Cited by 1,263
Self-citationApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy
Initiative, A. D. N., Shi, Y., Yamada, K., Liddelow, S. A., Smith, S. T., Zhao, L., Luo, W., Tsai, R. M., Spina, S., Grinberg, L. T., et al. (2017) · Nature · doi:10.1038/nature24016 · Cited by 1,220
Self-citationApolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy
Bu, G. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2620 · Cited by 1,168
Flagged first, then by citations
Cited by
Sorted by citations
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Fernández-Calle, R., Konings, S. C., Frontiñán-Rubio, J., García-Revilla, J., Camprubí-Ferrer, L., Svensson, M., Martinson, I., Boza-Serrano, A., Venero, J. L., Nielsen, H. M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00566-4 · Cited by 278
APOE mediated neuroinflammation and neurodegeneration in Alzheimer’s disease
Parhizkar, S., & Holtzman, D. M. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101594 · Cited by 255
Self-citationCell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
Lipid-accumulated reactive astrocytes promote disease progression in epilepsy
Chen, Z.-P., Wang, S., Zhao, X., Fang, W., Wang, Z., Ye, H., Wang, M.-J., Ke, L., Huang, T., Lv, P., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01288-6 · Cited by 214
Multifaceted roles of APOE in Alzheimer disease
Jackson, R. J., Hyman, B. T., & Serrano-Pozo, A. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-00988-2 · Cited by 193
TREM2 dependent and independent functions of microglia in Alzheimer’s disease
Hou, J., Chen, Y., Grajales-Reyes, G., & Colonna, M. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00588-y · Cited by 191
Insights into Alzheimer’s disease from single-cell genomic approaches
Murdock, M. H., & Tsai, L.-H. (2023) · Nature Neuroscience · doi:10.1038/s41593-022-01222-2 · Cited by 148
Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits
Koutsodendris, N., Blumenfeld, J., Agrawal, A., Traglia, M., Grone, B., Zilberter, M., Yip, O., Rao, A., Nelson, M. R., Hao, Y., et al. (2023) · Nature Aging · doi:10.1038/s43587-023-00368-3 · Cited by 132
TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4.
Gratuze, M., Schlachetzki, J. C. M., D’Oliveira Albanus, R., Jain, N., Novotny, B., Brase, L., Rodriguez, L., Mansel, C., Kipnis, M., O’Brien, S., et al. (2023) · Neuron · doi:10.1016/j.neuron.2022.10.022 · Cited by 115
Self-citationElevating microglia TREM2 reduces amyloid seeding and suppresses disease-associated microglia
Zhao, N., Qiao, W., Li, F., Ren, Y., Zheng, J., Martens, Y. A., Wang, X., Li, L., Liu, C., Chen, K., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20212479 · Cited by 116
TFEB–vacuolar ATPase signaling regulates lysosomal function and microglial activation in tauopathy
Wang, B., Martini‐Stoica, H., Qi, C., Lu, T., Wang, S., Xiong, W., Qi, Y., Xu, Y., Sardiello, M., Li, H., et al. (2023) · Nature Neuroscience · doi:10.1038/s41593-023-01494-2 · Cited by 107
Inflammatory Cascade in Alzheimer’s Disease Pathogenesis: A Review of Experimental Findings
de Oliveira, J., Kucharska, E., Garcez, M. L., Rodrigues, M. S., Quevedo, J., Moreno‐González, I., & Budni, J. (2021) · Cells · doi:10.3390/cells10102581 · Cited by 110
Roles of ApoE4 on the Pathogenesis in Alzheimer’s Disease and the Potential Therapeutic Approaches
Sun, Y.-Y., Wang, Z., & Huang, H. (2023) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-023-01365-1 · Cited by 102
Guo, J. L., Braun, D., Fitzgerald, G. A., Hsieh, Y.-T., Rougé, L., Litvinchuk, A., Steffek, M., Propson, N. E., Heffner, C. M., Discenza, C., et al. (2025) · Cell · doi:10.1016/j.cell.2024.10.027 · Cited by 91
“However, important roles were shown for LDLR in modulating AD pathologies, 57–59 in part via uptake and clearance of A b by astrocytes.”
Self-citationApolipoprotein E in Alzheimer’s disease: molecular insights and therapeutic opportunities
Belaidi, A. A., Bush, A. I., & Ayton, S. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00843-y · Cited by 91
Piccialli, I., Tedeschi, V., Caputo, L., D’Errico, S., Ciccone, R., De Feo, V., Secondo, A., & Pannaccione, A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.876614 · Cited by 73
Cashikar, A. G., Toral-Rios, D., Timm, D., Romero, J., Strickland, M., Long, J. M., Han, X., Holtzman, D. M., & Paul, S. M. (2023) · Journal of Lipid Research · doi:10.1016/j.jlr.2023.100350 · Cited by 72
Self-citationApolipoprotein E in Alzheimer’s disease trajectories and the next-generation clinical care pathway
Narasimhan, S., Holtzman, D. M., Apostolova, L. G., Cruchaga, C., Masters, C. L., Hardy, J., Villemagne, V. L., Bell, J. S., Cho, M., & Hampel, H. J. (2024) · Nature Neuroscience · doi:10.1038/s41593-024-01669-5 · Cited by 70
Self-citationYang, F., Zhao, D., Cheng, M., Liu, Y., Chen, Z., Chang, J. K., & Dou, Y. (2023) · ACS Nano · doi:10.1021/acsnano.3c03232 · Cited by 65
Izzy, S., Yahya, T., Albastaki, O., Abou‐El‐Hassan, H., Aronchik, M., Cao, T., de Oliveira, M. G., Lu, K.-J., Moreira, T. G., da Silva, P., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-01877-7 · Cited by 65
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Li, Y., Macyczko, J. R., Liu, C.-C., & Bu, G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.011 · Cited by 61
Qiu, Y., Shen, X., Ravid, O., Atrakchi, D., Rand, D., Wight, A. E., Kim, H.-J., Zaltsman, S. L., Cooper, I., Beeri, M. S., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2218915120 · Cited by 62
Hu, Y., & Tao, W. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.01.006 · Cited by 64
Role of Receptors in Relation to Plaques and Tangles in Alzheimer’s Disease Pathology
Sharma, K., Pradhan, S., Duffy, L. K., Yeasmin, S., Bhattarai, N., & Schulte, M. K. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312987 · Cited by 59
Implications of glial metabolic dysregulation in the pathophysiology of neurodegenerative diseases
Afridi, R., Rahman, M. H., & Suk, K. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105874 · Cited by 53
Alzheimer’s disease pathogenesis: standing at the crossroad of lipid metabolism and immune response
Wang, Z., Zhang, L., & Qin, C. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00857-6 · Cited by 60
Gao, S., Jiang, Y., Chen, Z., Zhao, X.-Q., Gu, J., Wu, H., Liao, Y., Sun, H., Wang, J., & Chen, W. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221216162606 · Cited by 51
Incontro, S., Musella, M. L., Sammari, M., Scala, C. D., Fantini, J., & Debanne, D. (2024) · Physiological Reviews · doi:10.1152/physrev.00004.2024 · Cited by 51
NHE6 depletion corrects ApoE4-mediated synaptic impairments and reduces amyloid plaque load
Pohlkamp, T., Xian, X., Wong, C. H., Durakoglugil, M. S., Werthmann, G. C., Saido, T. C., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · eLife · doi:10.7554/elife.72034 · Cited by 46
Alzheimer’s genes in microglia: a risk worth investigating
Sudwarts, A., & Thinakaran, G. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00679-4 · Cited by 52
The vascular contribution of apolipoprotein E to Alzheimer’s disease
Chen, F., Zhao, J., Meng, F., He, F., Ni, J., & Fu, Y. (2024) · Brain · doi:10.1093/brain/awae156 · Cited by 39
Synapses, Microglia, and Lipids in Alzheimer’s Disease
Paasila, P. J., Aramideh, J. A., Sutherland, G. T., & Graeber, M. B. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.778822 · Cited by 40
The role of ApoE-mediated microglial lipid metabolism in brain aging and disease
Yen, J.-H. J., & Yu, I.-C. I. (2023) · Immunometabolism · doi:10.1097/in9.0000000000000018 · Cited by 38
Relationship between Brain Metabolic Disorders and Cognitive Impairment: LDL Receptor Defect
Hong, D.-Y., Lee, D.-H., Lee, J., Lee, E.-C., Park, S.-W., Lee, M. R., & Oh, J. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158384 · Cited by 38
Lipid metabolism transcriptomics of murine microglia in Alzheimer’s disease and neuroinflammation
Shippy, D. C., & Ulland, T. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-41897-6 · Cited by 35
Lee, J., Lee, H., Lee, H. G., Shin, M., Shin, M.-G., Seo, J., Lee, E. J., Park, S. A., & Park, S. (2023) · Nature Communications · doi:10.1038/s41467-023-44319-3 · Cited by 37
Lipid and lipoprotein metabolism in microglia: Alzheimer’s disease mechanisms and interventions
Sprenger, K. G., Lietzke, E. E., Melchior, J. T., & Bruce, K. D. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100872 · Cited by 42
APOE ε4 genotype, amyloid-β, and sex interact to predict tau in regions of high APOE mRNA expression
Dincer, A., Chen, C. D., McKay, N. S., Koenig, L. N., McCullough, A. A., Flores, S. E., Keefe, S., Schultz, S. A., Feldman, R. L., Joseph‐Mathurin, N., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abl7646 · Cited by 34
Self-citationLipids: Emerging Players of Microglial Biology
Prakash, P., Randolph, C. E., Walker, K. A., & Chopra, G. (2024) · Glia · doi:10.1002/glia.24654 · Cited by 41
Preman, P., Moechars, D., Fertan, E., Wolfs, L., Serneels, L., Shah, D., Lamote, J., Poovathingal, S., Snellinx, A., Mancuso, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00162-7 · Cited by 32
Glial polarization in neurological diseases: Molecular mechanisms and therapeutic opportunities
Liu, Y., Wu, L., Peng, W., & Mao, X. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102638 · Cited by 32
Convergence of sepsis-associated encephalopathy pathogenesis onto microglia
Xiao, D., Wang, X., Liang, W., Yang, Y., Du, Y., Liu, C., Xu, F., Yang, Y., Wei, M., & Yang, G. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06635-8 · Cited by 33
Modulations of bioactive lipids and their receptors in postmortem Alzheimer’s disease brains
Kurano, M., Saito, Y., Uranbileg, B., Saigusa, D., Kano, K., Aoki, J., & Yatomi, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1066578 · Cited by 30
Cholesterol Metabolism in Neurodegenerative Diseases
He, K., Zhao, Z., Zhang, J., Li, D., Wang, S., & Liu, Q. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0674 · Cited by 30
Tran, K. M., Kwang, N. E., Butler, C. A., Gomez-Arboledas, A., Kawauchi, S., Mar, C., Chao, D., Barahona, R. A., Da Cunha, C., Tsourmas, K. I., et al. (2025) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00793-x · Cited by 28
Ldl-stimulated microglial activation exacerbates ischemic white matter damage
Zhou, L., Chu, Y., Dong, M., Yang, S., Chen, M., Tang, Y., Pang, X., You, Y., Wu, L., Wang, W., et al. (2024) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2024.04.014 · Cited by 28
Zhai, C., Wang, Z., Cai, J., Fang, L., Li, X., Jiang, K., Shen, Y., Wang, Y., Xu, X., Liu, W., et al. (2024) · Experimental Neurology · doi:10.1016/j.expneurol.2024.114844 · Cited by 29
de Frutos‐Lucas, J., Sewell, K. R., García‐Colomo, A., Markovic, S. J., Erickson, K. I., & Brown, B. M. (2023) · Alzheimer s Research & Therapy · doi:10.1186/s13195-023-01170-4 · Cited by 26
Torshizi, A. D., Truong, D. T., Hou, L., Smets, B., Whelan, C. D., & Li, S. (2024) · Nature Communications · doi:10.1038/s41467-024-50718-x · Cited by 27
Chen, K., Li, F., Zhang, S., Chen, Y., Ikezu, T. C., Li, Z., Martens, Y. A., Qiao, W., Meneses, A. D., Zhu, Y., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03420-8 · Cited by 29
Cooper, O., Hallett, P. J., & Ole Isacson, A. (2022) · FEBS Journal · doi:10.1111/febs.16638 · Cited by 26
de Oliveira, J., Moreira, E. L. G., & Bem, A. F. D. (2023) · Ageing Research Reviews · doi:10.1016/j.arr.2023.102149 · Cited by 26
Qu, W., Canoll, P., & Hargus, G. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.006 · Cited by 24
Wang, S., Wu, L., Xie, Y., Ge, S., Wu, Y., Chen, L., Yi, L., Yang, J., Duan, F., & Huang, L. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118412 · Cited by 20
New insights into innate immunity in Alzheimer’s disease: From APOE protective variants to therapies
Chen, Y., & Holtzman, D. M. (2024) · Trends in Immunology · doi:10.1016/j.it.2024.08.001 · Cited by 19
Self-citationGolden, L. R., Siano, D. S., Stephens, I. O., MacLean, S. M., Saito, K., Nolt, G. L., Funnell, J. L., Pallerla, A. V., Lee, S., Smith, C., et al. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02094-y · Cited by 18
Zhou, Y., Huang, Z., Lin, B., Ma, M., Hao, Y., Liu, J., Xu, W., Huang, G., Mo, W., Wang, X., et al. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01235-w · Cited by 19
Zhang, W.-X., Yang, Y.-L., Yu, J., Jia, L., & Huang, H. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152335 · Cited by 19
Emerging roles for innate and adaptive immunity in tauopathies
Johnson, A. M., & Lukens, J. R. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116232 · Cited by 19
Lou, T.-W., Tao, B., & Chen, M. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.01.032 · Cited by 17
Positron Emission Tomography in Animal Models of Tauopathies
Cao, L., Kong, Y., Ji, B., Ren, Y., Guan, Y., & Ni, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.761913 · Cited by 14
Sánchez-Melgar, A., Izquierdo-Ramírez, P. J., Griñán‐Ferré, C., Pallàs, M., Martín, M., & Albasanz, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147580 · Cited by 17
The Evolution of Experimental Rodent Models for Prion Diseases
DeFranco, J. P., & Telling, G. C. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70039 · Cited by 15
A novel Lgi1 mutation causes white matter abnormalities and impairs motor coordination in mice
Teng, X., Hu, P., Chen, Y., Zang, Y., Ye, X., Ou, J., Chen, G., & Shi, Y. S. (2022) · The FASEB Journal · doi:10.1096/fj.202101652r · Cited by 14
Self-citationApoE-calypse tau: ApoE–tau synergy in Alzheimer’s disease
Lennol, M. P., Bordier, C., Kamelher, L., Ulrich, J. D., Holtzman, D. M., & Gratuze, M. (2025) · The Journal of Experimental Medicine · doi:10.1084/jem.20250965 · Cited by 14
Self-citationFeng, S., Li, J., Liu, T., Huang, S., Chen, X., Liu, S., Zhou, J., Zhao, H., & Hong, Y. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01263 · Cited by 13
Chronic IL-21 drives neuroinflammation and promotes lipid accumulation in microglia
Oyamada, H. A. A., Ying, Y., Agrawal, S., Liu, A., Subramanian, V. S., Bento, C. A. M., & Agrawal, A. (2025) · Immunity & Ageing · doi:10.1186/s12979-025-00510-2 · Cited by 14
Yang, X., Yao, K., Zhang, M., Zhang, W., & Zu, H. (2025) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2025.111321 · Cited by 12
Metabolic Disturbance of High-Saturated Fatty Acid Diet in Cognitive Preservation
Rivas-Domínguez, A., Mohamed-Mohamed, H., Jiménez-Palomares, M., García‐Morales, V., Martínez-López, L., Orta, M. L., Ramos‐Rodríguez, J. J., & Bermúdez, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24098042 · Cited by 11
Functional insight into LOAD-associated microglial response genes
Jonas, L. A., Jain, T., & Li, Y. (2022) · Open Biology · doi:10.1098/rsob.210280 · Cited by 13
Contextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer’s Disease
Lalwani, R. C., Volmar, C., Wahlestedt, C., Webster, K. A., & Shehadeh, L. A. (2023) · Biomedicines · doi:10.3390/biomedicines11123232 · Cited by 13
Rubinski, A., Dewenter, A., Zheng, L., Franzmeier, N., Stephenson, H. G., Deming, Y. K., Duering, M., Gesierich, B. G., Denecke, J., Pham, A.-V., et al. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06530-8 · Cited by 11
Tau aggregation and its relation to selected forms of neuronal cell death
Tolkovsky, A. M., & Spillantini, M. G. (2021) · Essays in Biochemistry · doi:10.1042/ebc20210030 · Cited by 13
Alzheimer's disease: from molecular pathways to therapies
Feng, J.-Q., Yang, L.-L., Ya-xi, L., & Yao, X. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00443-2 · Cited by 10
Tau aggregation and its relation to selected forms of neuronal cell death.
Tolkovsky, A. M., & Spillantini, M. G. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.80530 · Cited by 9
Espinosa-Cabello, J. M., Castellano, J. M., Garcia-Rodriguez, S., Quintero‐Flórez, A., Carrasquilla, N., & Perona, J. S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147706 · Cited by 9
Mendiola, A. S., Tognatta, R., Yan, Z., & Akassoglou, K. (2021) · Neuron · doi:10.1016/j.neuron.2021.07.013 · Cited by 8
Gong, Z., Laporte, J. P., Guo, A. Y., Bilgel, M., Bae, J., Fox, N. Y., de Rouen, A., Zhang, N., Taranath, A., de Cabo, R., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci196638 · Cited by 7
“For tau pathology, alterations in WM integrity were observed in a transgenic mouse model of fibrillar tau (21, 22), preceding the emergence of tau pathology (21), with clinical investigations suggesting a role of WM hyperintensities in tau pathology in the AD spectrum (23).”
Biomarkers in Ataxia-Telangiectasia: a Systematic Review
Tiet, M. Y., Biatricia, G. U. T. U., Springall-Jeggo, P., Coman, D. J., Willemsen, M. A. A. P., van Os, N., Doria, M., Donath, H., Schubert, R., Dineen, R. A., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-024-12766-7 · Cited by 8
Association of rare APOE missense variants with Alzheimer's disease in the Japanese population
Miyashita, A., Obinata, A., Hara, N., Mitsumori, R., Kaneda, D., Hashizume, Y., Sano, T., Takao, M., Gabdulkhaev, R., Tada, M., et al. (2025) · Journal of Alzheimer’s Disease · doi:10.1177/13872877251340710 · Cited by 5
Local molecular and connectomic contributions of tau-related neurodegeneration
Nabizadeh, F., Initiative, A. D. N., Weiner, M. W., Aisen, P., Petersen, R. C., Jack, C. R., Jagust, W., Trojanowski, J. Q., Toga, A. W., Beckett, L. A., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01339-1 · Cited by 5
Self-citationTargeting the complement-mTOR-autophagy axis: the role of apolipoprotein E in depression
Li, Y., Xu, C., Liu, J., Guo, M., Wang, J., Bai, X., Cheng, Y., Luan, X., Pei, H., Zhang, C., et al. (2025) · BMC Biology · doi:10.1186/s12915-025-02301-z · Cited by 5
Weller, A. E., Doyle, G. A. R., Reiner, B. C., Crist, R. C., & Berrettini, W. H. (2021) · Neuroscience Research · doi:10.1016/j.neures.2021.10.010 · Cited by 5
Wang, L., Shao, C., Han, C., Li, P., Wang, F., Wang, Y., & Li, J. (2022) · PubMed · Cited by 6
LRP10 and α-synuclein transmission in Lewy body diseases
Mascaro, A. C., Grochowska, M. M., Boumeester, V., Dits, N. F. J., Bilgiҫ, E. N., Breedveld, G. J., Vergouw, L. J. M., de Jong, F. J., van Royen, M. E., Bonifati, V., et al. (2024) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-024-05135-0 · Cited by 6
The Role of Oligodendrocytes in Alzheimer’s Disease Pathogenesis and Therapy
Guo, S., Yu, X., & Zhang, H. (2025) · Neuroglia · doi:10.3390/neuroglia6040046 · Cited by 5
Proteomic analysis of postprandial high-density lipoproteins in healthy subjects
Grao‐Cruces, E., Santos-Mejías, A., Ortea, I., Marquez‐Paradas, E., Martín, M. E., Barrientos‐Trigo, S., Bermúdez, B., & la Paz, S. M. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.11.187 · Cited by 4
LDL receptor upregulation reduces tau pathology
Wood, H. B. (2021) · Nature Reviews Neurology · doi:10.1038/s41582-021-00535-3 · Cited by 4
Meco, A. D., Kemal, S., Popović, J., Chandra, S., Sadleir, K. R., & Vassar, R. J. (2022) · Current Alzheimer Research · doi:10.2174/1567205019666220509143823 · Cited by 5
Bagaria, J., Moon, Y., Bagyinszky, E., Shim, K. H., An, S. S. A., Kim, S., & Han, S. H. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.899644 · Cited by 4
Early-onset Alzheimer’s disease due to novel LDLR gene mutation
Perković, R., Frančić, M., Petrović, R., Ozretić, D., Škara, S., Pećin, I., & Borovečki, F. (2023) · Acta Neurologica Belgica · doi:10.1007/s13760-023-02316-9 · Cited by 5
Шахтшнейдер, Е. В., Иванощук, Д. Е., Ragino, Y. I., Fishman, V., Polonskaya, Y. V., Kashtanova, E. V., Chernyavsky, A. M., Murashov, I. S., & Voevoda, M. I. (2022) · Сибирский журнал клинической и экспериментальной медицины · doi:10.29001/2073-8552-2021-36-4-156-163 · Cited by 3
NHE6-Depletion Corrects ApoE4-Mediated Synaptic Impairments and Reduces Amyloid Plaque LoadPreprint
Pohlkamp, T., Xian, X., Wong, C. H. Y., Durakoglugil, M. S., Werthmann, G. C., Saido, T., Evers, B. M., White, C. L., Connor, J., Hammer, R. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.22.436385 · Cited by 4
ApoE expression across the CNS: Who, What, Where, When, and How (much)?
Nolt, G. L., Lucido, C. C., Smith, L. M., & Johnson, L. A. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00028-x · Cited by 2
Deletion of neuronal Idol ameliorates Alzheimer's disease–related pathologies via APOE receptors
Karahan, H., Hartigan, K., Al‐Amin, M. M., John, S. K., McCord, B., Wijeratne, H. R. S., Acri, D. J., Smith, D. C., Dabin, L. C., Cordero, H. M. R., et al. (2025) · Alzheimer's & Dementia · doi:10.1002/alz.70949 · Cited by 2
“It is notable that overexpression of Ldlr also reduced tau pathology and neurodegeneration in a tauopathy mouse model, 74 further supporting the beneficial effects of increasing LDLR in AD.”
NLRP3 is crucial for macrophage metabolic reprogramming during Vibrio vulnificus infection
Jiang, Y.-L., Huang, X.-H., Zhu, W., Wei, S.-Q., Li, J., Lin, H.-N., Bian, H.-K., Wu, C., Miao, X.-J., Lou, Y., et al. (2025) · Microbiology Spectrum · doi:10.1128/spectrum.00230-25 · Cited by 2
Guo, X., Xu, J., Lu, X., Zheng, X., Chen, X., Sun, Z., Shen, B., Tang, H., Duan, Y., Zhou, Z., et al. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400254 · Cited by 2
CD8 + T cells are primed by cDC1 and exacerbate tau-mediated neurodegenerationPreprint
Hu, H., Lin, P. B., Zeng, C., Sharma, P., Li, Y., Jiang, H., Nulman, J., Ohara, R. A., Wu, T., Li, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.26.708260 · Cited by 2
Self-citation
Metadata
- Authors
- Shi, Y., Andhey, P. S., Ising, C., Wang, K., Snipes, L. L., Boyer, K., Lawson, S., Yamada, K., Qin, W., Manis, M., Serrano, J. R., Benitez, B. A., Schmidt, R. E., Artyomov, M., Ulrich, J. D., & Holtzman, D. M.
- Affiliations
- Washington University in St. Louis (US)
- University Hospital Bonn (DE)
- The University of Tokyo (JP)
- Corresponding author
- Ulrich, Jason D.
- Holtzman, David M.
- ORCID
- Venue
- Neuron
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 109
- Issue
- 15
- Pages
- 2413-2426.e7
- ISSN
- 0896-6273 (ISSN-L)
- PMC
- PMC8349883
- OpenAlex
- W3177458716
- Semantic Scholar
- 1544f9b83b6ce89b91dbee8712a9dde8dab78e8d
- Cited by
- 135
- References
- 55
- Citations by year
- 2026: 21 · 2025: 31 · 2024: 25 · 2023: 21 · 2022: 28 · 2021: 9
- FWCI
- 13.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 368 d)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
- Locations
- Neuron (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- DZNE Pub (submittedVersion)
- Funders
- JPB Foundation
- National Institutes of Health (AG047644, NS090934)
- University of Washington
- Genentech
- Diabetes Research Center
- Tau Consortium
- Merck
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- LDL receptor, apolipoprotein E, tauopathy, Alzheimer's disease, microglial activation, oligodendrocyte precursor cells, myelin integrity, reactive astrocytes, ion channels, neurotransmitter receptors, neurodegeneration
- MeSH terms
- Animals, Apolipoproteins E, Male, Nerve Degeneration, Receptors, LDL, Microglia, Mice, Knockout, Tauopathies, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
